As at May 20, 2022Show prices
SaskWorks Diversified (Class A - Series A) 23.9952
SaskWorks Diversified (Class A - Series B) 24.5637
SaskWorks Diversified (Class A - Series F) 27.6426
SaskWorks Resources (Class R - Series A) 20.6995
SaskWorks Resources (Class R - Series B) 22.1958
SaskWorks Resources (Class R - Series F) 20.9321
Brent Zettl, President and CEO, CanniMed Therapeutics Inc.(TSX:CMED) and Rob Duguid , Chief Investment Officer, PFM Capital Inc. joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016. For more information, please visit www.cannimed.ca
Please select the option that best describes you:
